According to successful experience in BRAF inhibitors targeting BRAF mutant cancers like melanoma [30], two patients of recurrent CPs with BRAF V600E mutation were subscribed with BRAF/MEK inhibitors [12, 13]. This evidence concerns the gene MAP2K7 and cancer.